CNMD
CONMED Corporation
Price Chart
Latest Quote
$43.20
-1.81 (-4.02%)
Current Price
| Previous Close | $45.01 |
| Open | $44.76 |
| Day High | $44.98 |
| Day Low | $42.65 |
| Volume | 400,901 |
Stock Information
| Quarterly Dividend / Yield | $0.80 / 1.78% |
| Shares Outstanding | 30.11M |
| Quarterly Dividend Yield | 1.78% |
| Quarterly Dividend | $0.80 |
| Total Debt | $860.87M |
| Cash Equivalents | $35.03M |
| Revenue | $1.37B |
| Net Income | $54.85M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $1.30B |
| P/E Ratio | 25.41 |
| EPS (TTM) | $1.70 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.13B |
| Sales | $1.37B |
| Income | $54.85M |
| Book/sh | $33.76 |
| Cash/sh | $1.16 |
| Employees | 4K |
Financial Ratios
| Quick Ratio | 0.90 |
| Current Ratio | 2.29 |
| Debt/Eq | 84.59 |
| EPS Growth TTM | 129.10% |
Returns & Margins
| ROA | 3.76% |
| ROE | 5.50% |
| Gross Margin | 54.20% |
| Operating Margin | 10.61% |
| Profit Margin | 4.00% |
Ownership
| Insider Ownership | 0.43% |
| Institutional Ownership | 116.76% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 9.15 |
| PEG | 1.84 |
| P/S | 0.95 |
| P/B | 1.28 |
Analyst Data
| Recommendation | hold |
| Target Price | $39.00 |
Technical Indicators
| SMA20 | $36.59 |
| SMA50 | $35.98 |
| SMA200 | $40.02 |
| RSI | 66.73 |
| ATR | 2.4536 |
| Shares Float | 29.81M |
| Short Float | 9.99% |
| Short Ratio | 4.03 |
| Volatility | 0.93 |
| Rel Volume | 0.61 |
Performance History
| Week | +12.27% |
| Month | +24.96% |
| Quarter | +13.95% |
| 6 Months | +3.90% |
| YTD | +6.61% |
| Year | -13.17% |
| 3 Years | -66.94% |
| 5 Years | -66.83% |
| 10 Years | -3.60% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $43.20 | 504,900 |
| 2026-07-16 | $45.01 | 766,200 |
| 2026-07-15 | $42.79 | 870,100 |
| 2026-07-14 | $41.75 | 994,300 |
| 2026-07-13 | $42.41 | 2,454,500 |
| 2026-07-10 | $38.48 | 1,443,400 |
| 2026-07-09 | $36.69 | 1,182,900 |
| 2026-07-08 | $33.59 | 533,500 |
| 2026-07-07 | $34.24 | 433,300 |
| 2026-07-06 | $35.11 | 691,900 |
| 2026-07-02 | $33.83 | 437,000 |
| 2026-07-01 | $32.76 | 397,400 |
| 2026-06-30 | $32.73 | 460,100 |
| 2026-06-29 | $34.41 | 727,600 |
| 2026-06-26 | $35.95 | 843,800 |
| 2026-06-25 | $34.56 | 371,000 |
| 2026-06-24 | $35.40 | 500,700 |
| 2026-06-23 | $33.80 | 581,500 |
| 2026-06-22 | $32.54 | 1,015,900 |
| 2026-06-18 | $32.58 | 1,228,100 |
About CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.
đ° Latest News
1 Russell 2000 Stock to Own for Decades and 2 We Avoid
StockStory âĸ 2026-07-16T12:17:22Z
CONMED (CNMD) Stock Trades Up, Here Is Why
StockStory âĸ 2026-07-13T22:30:39Z
Conmed Surges Within Striking Distance Of A Breakout On Buyout Rumors
Investor's Business Daily âĸ 2026-07-13T20:53:38Z
Why This Medical Technology Stock Is Up 10%
Barrons.com âĸ 2026-07-13T20:49:00Z
Sector Update: Healthcare Stocks Advance Late Afternoon
MT Newswires âĸ 2026-07-13T19:34:41ZCNMD Stock Hits Highest Level In Over Four Months â Why JPMorgan Believes Firm Would Be Highly Attractive To âFinancial Acquirersâ
Stocktwits âĸ 2026-07-13T16:34:26Z
CNMD Stock Surges As Much As 10% After-Hours On Reports Of Private Equity Takeover Interest
Stocktwits âĸ 2026-07-11T00:28:32Z
3 Healthcare Stocks We Think Twice About
StockStory âĸ 2026-07-09T11:49:00Z
3 Value Stocks Walking a Fine Line
StockStory âĸ 2026-07-06T11:08:01Z
CONMED (CNMD) Stock Fair Value Moves Lower As Analysts Turn More Cautious
Simply Wall St. âĸ 2026-07-04T01:09:07Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $624,249,000 | $573,983,000 | $568,499,000 | $474,227,000 |
| Cost Of Revenue | $624,249,000 | $573,983,000 | $568,499,000 | $474,227,000 |
| Total Revenue | $1,374,724,000 | $1,307,015,000 | $1,244,744,000 | $1,045,472,000 |
| Operating Revenue | $1,374,724,000 | $1,307,015,000 | $1,244,744,000 | $1,045,472,000 |
| Expenses | ||||
| Interest Expense | $31,087,000 | $37,297,000 | $39,775,000 | $28,905,000 |
| Total Expenses | $1,272,102,000 | $1,106,689,000 | $1,124,141,000 | $975,418,000 |
| Other Income Expense | $-418,000 | - | - | $-112,011,000 |
| Other Non Operating Income Expenses | $-418,000 | - | - | $-112,011,000 |
| Net Non Operating Interest Income Expense | $-31,087,000 | $-37,297,000 | $-39,775,000 | $-28,905,000 |
| Interest Expense Non Operating | $31,087,000 | $37,297,000 | $39,775,000 | $28,905,000 |
| Operating Expense | $647,853,000 | $532,706,000 | $555,642,000 | $501,191,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $47,055,000 | $132,423,000 | $64,459,000 | $-80,582,000 |
| Net Interest Income | $-31,087,000 | $-37,297,000 | $-39,775,000 | $-28,905,000 |
| Normalized Income | $47,055,000 | $132,423,000 | $64,459,000 | $-80,582,000 |
| Net Income From Continuing And Discontinued Operation | $47,055,000 | $132,423,000 | $64,459,000 | $-80,582,000 |
| Total Operating Income As Reported | $102,622,000 | $200,326,000 | $120,603,000 | $70,054,000 |
| Net Income Common Stockholders | $47,055,000 | $132,423,000 | $64,459,000 | $-80,582,000 |
| Net Income | $47,055,000 | $132,423,000 | $64,459,000 | $-80,582,000 |
| Net Income Including Noncontrolling Interests | $47,055,000 | $132,423,000 | $64,459,000 | $-80,582,000 |
| Net Income Continuous Operations | $47,055,000 | $132,423,000 | $64,459,000 | $-80,582,000 |
| Pretax Income | $71,117,000 | $163,029,000 | $80,828,000 | $-70,862,000 |
| Operating Income | $102,622,000 | $200,326,000 | $120,603,000 | $70,054,000 |
| Gross Profit | $750,475,000 | $733,032,000 | $676,245,000 | $571,245,000 |
| Per Share | ||||
| Diluted EPS | $1.51 | $4.25 | $2.04 | $-2.68 |
| Basic EPS | $1.52 | $4.29 | $2.10 | $-2.68 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $176,485,000 | $272,183,000 | $192,477,000 | $27,562,000 |
| Reconciled Depreciation | $74,281,000 | $71,857,000 | $71,874,000 | $69,519,000 |
| EBITDA (Bullshit earnings) | $176,485,000 | $272,183,000 | $192,477,000 | $27,562,000 |
| EBIT | $102,204,000 | $200,326,000 | $120,603,000 | $-41,957,000 |
| Diluted Average Shares | $31,149,000 | $31,150,000 | $31,548,000 | $30,040,000 |
| Basic Average Shares | $31,036,000 | $30,846,000 | $30,668,000 | $30,040,000 |
| Diluted NI Availto Com Stockholders | $47,055,000 | $132,423,000 | $64,459,000 | $-80,582,000 |
| Tax Provision | $24,062,000 | $30,606,000 | $16,369,000 | $9,720,000 |
| Research And Development | $55,884,000 | $54,426,000 | $52,602,000 | $47,152,000 |
| Selling General And Administration | $591,969,000 | $478,280,000 | $503,040,000 | $454,039,000 |
Fetched: 2026-07-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-355,965,000 | $-460,340,000 | $-622,106,000 | $-751,683,000 |
| Total Assets | $2,325,749,000 | $2,306,247,000 | $2,300,021,000 | $2,297,592,000 |
| Total Non Current Assets | $1,652,889,000 | $1,666,240,000 | $1,684,372,000 | $1,716,366,000 |
| Other Non Current Assets | $137,187,000 | $116,357,000 | $96,111,000 | $93,877,000 |
| Non Current Deferred Assets | $13,309,000 | $11,069,000 | $11,211,000 | $9,650,000 |
| Non Current Deferred Taxes Assets | $13,309,000 | $11,069,000 | $11,211,000 | $9,650,000 |
| Goodwill And Other Intangible Assets | $1,389,062,000 | $1,423,021,000 | $1,456,328,000 | $1,497,228,000 |
| Other Intangible Assets | $582,051,000 | $617,663,000 | $649,484,000 | $681,799,000 |
| Current Assets | $672,860,000 | $640,007,000 | $615,649,000 | $581,226,000 |
| Other Current Assets | $28,669,000 | $31,096,000 | $30,750,000 | $28,619,000 |
| Inventory | $355,544,000 | $346,719,000 | $318,324,000 | $332,320,000 |
| Receivables | $247,830,000 | $237,733,000 | $242,279,000 | $191,345,000 |
| Accounts Receivable | $247,830,000 | $237,733,000 | $242,279,000 | $191,345,000 |
| Allowance For Doubtful Accounts Receivable | $-6,300,000 | $-5,739,000 | $-6,034,000 | $-5,508,000 |
| Gross Accounts Receivable | $254,130,000 | $243,472,000 | $248,313,000 | $196,853,000 |
| Cash Cash Equivalents And Short Term Investments | $40,817,000 | $24,459,000 | $24,296,000 | $28,942,000 |
| Cash And Cash Equivalents | $40,817,000 | $24,459,000 | $24,296,000 | $28,942,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $794,125,000 | $881,322,000 | $949,552,000 | $1,025,880,000 |
| Total Debt | $834,942,000 | $905,781,000 | $973,848,000 | $1,054,822,000 |
| Long Term Debt And Capital Lease Obligation | $834,230,000 | $905,066,000 | $973,140,000 | $985,076,000 |
| Long Term Debt | $834,230,000 | $905,066,000 | $973,140,000 | $985,076,000 |
| Current Debt And Capital Lease Obligation | $712,000 | $715,000 | $708,000 | $69,746,000 |
| Current Debt | $712,000 | $715,000 | $708,000 | $69,746,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,292,652,000 | $1,343,566,000 | $1,465,799,000 | $1,552,047,000 |
| Total Non Current Liabilities Net Minority Interest | $977,611,000 | $1,065,436,000 | $1,155,070,000 | $1,255,495,000 |
| Other Non Current Liabilities | $63,851,000 | $86,294,000 | $121,028,000 | $203,694,000 |
| Non Current Deferred Liabilities | $79,530,000 | $74,076,000 | $60,902,000 | $66,725,000 |
| Non Current Deferred Taxes Liabilities | $79,530,000 | $74,076,000 | $60,902,000 | $66,725,000 |
| Current Liabilities | $315,041,000 | $278,130,000 | $310,729,000 | $296,552,000 |
| Other Current Liabilities | $138,542,000 | $109,799,000 | $151,728,000 | $98,680,000 |
| Payables And Accrued Expenses | $93,648,000 | $102,248,000 | $88,224,000 | $73,393,000 |
| Payables | $93,648,000 | $102,248,000 | $88,224,000 | $73,393,000 |
| Accounts Payable | $93,648,000 | $102,248,000 | $88,224,000 | $73,393,000 |
| Equity | ||||
| Common Stock Equity | $1,033,097,000 | $962,681,000 | $834,222,000 | $745,545,000 |
| Total Equity Gross Minority Interest | $1,033,097,000 | $962,681,000 | $834,222,000 | $745,545,000 |
| Stockholders Equity | $1,033,097,000 | $962,681,000 | $834,222,000 | $745,545,000 |
| Gains Losses Not Affecting Retained Earnings | $-46,295,000 | $-58,857,000 | $-50,170,000 | $-57,858,000 |
| Other Equity Adjustments | $-46,295,000 | $-58,857,000 | $-50,170,000 | $-57,858,000 |
| Retained Earnings | $588,766,000 | $560,277,000 | $452,531,000 | $412,631,000 |
| Other | ||||
| Treasury Shares Number | $328,097 | $397,860 | $534,000 | $811,532 |
| Ordinary Shares Number | $30,971,097 | $30,901,334 | $30,765,194 | $30,487,662 |
| Share Issued | $31,299,194 | $31,299,194 | $31,299,194 | $31,299,194 |
| Tangible Book Value | $-355,965,000 | $-460,340,000 | $-622,106,000 | $-751,683,000 |
| Invested Capital | $1,868,039,000 | $1,868,462,000 | $1,808,070,000 | $1,800,367,000 |
| Working Capital | $357,819,000 | $361,877,000 | $304,920,000 | $284,674,000 |
| Total Capitalization | $1,867,327,000 | $1,867,747,000 | $1,807,362,000 | $1,730,621,000 |
| Treasury Stock | $12,887,000 | $15,627,000 | $14,987,000 | $22,776,000 |
| Additional Paid In Capital | $503,200,000 | $476,575,000 | $446,535,000 | $413,235,000 |
| Capital Stock | $313,000 | $313,000 | $313,000 | $313,000 |
| Common Stock | $313,000 | $313,000 | $313,000 | $313,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $82,139,000 | $65,368,000 | $70,069,000 | $54,733,000 |
| Goodwill | $807,011,000 | $805,358,000 | $806,844,000 | $815,429,000 |
| Net PPE | $113,331,000 | $115,793,000 | $120,722,000 | $115,611,000 |
| Accumulated Depreciation | $-316,629,000 | $-305,419,000 | $-292,162,000 | $-277,536,000 |
| Gross PPE | $429,960,000 | $421,212,000 | $412,884,000 | $393,147,000 |
| Construction In Progress | $22,267,000 | $20,409,000 | $25,088,000 | $22,161,000 |
| Machinery Furniture Equipment | $299,182,000 | $295,839,000 | $283,470,000 | $269,745,000 |
| Buildings And Improvements | $104,484,000 | $100,937,000 | $100,299,000 | $97,214,000 |
| Land And Improvements | $4,027,000 | $4,027,000 | $4,027,000 | $4,027,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $212,651,000 | $200,691,000 | $181,599,000 | $195,477,000 |
| Work In Process | $33,263,000 | $31,300,000 | $29,463,000 | $26,166,000 |
| Raw Materials | $109,630,000 | $114,728,000 | $107,262,000 | $110,677,000 |
Fetched: 2026-07-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $150,883,000 | $153,884,000 | $106,316,000 | $11,580,000 |
| Operating Activities | ||||
| Operating Cash Flow | $170,689,000 | $166,968,000 | $125,348,000 | $33,365,000 |
| Cash Flow From Continuing Operating Activities | $170,689,000 | $166,968,000 | $125,348,000 | $33,365,000 |
| Operating Gains Losses | $363,000 | - | - | $8,886,000 |
| Investing Activities | ||||
| Capital Expenditure | $-19,806,000 | $-13,084,000 | $-19,032,000 | $-21,785,000 |
| Investing Cash Flow | $-20,956,000 | $-13,084,000 | $-20,032,000 | $-249,529,000 |
| Cash Flow From Continuing Investing Activities | $-20,956,000 | $-13,084,000 | $-20,032,000 | $-249,529,000 |
| Net Other Investing Changes | $-1,150,000 | - | $-1,000,000 | - |
| Financing Activities | ||||
| Financing Cash Flow | $-135,820,000 | $-151,000,000 | $-110,432,000 | $225,000,000 |
| Cash Flow From Continuing Financing Activities | $-135,820,000 | $-151,000,000 | $-110,432,000 | $225,000,000 |
| Net Other Financing Charges | $-36,487,000 | $-54,349,000 | $2,070,000 | $-115,525,000 |
| Cash Dividends Paid | $-24,746,000 | $-24,651,000 | $-24,502,000 | $-23,960,000 |
| Common Stock Dividend Paid | $-24,746,000 | $-24,651,000 | $-24,502,000 | $-23,960,000 |
| Other | ||||
| Repayment Of Debt | $-795,253,000 | $-823,000,000 | $-780,000,000 | $-897,981,000 |
| Issuance Of Debt | $720,666,000 | $751,000,000 | $692,000,000 | $1,260,000,000 |
| Interest Paid Supplemental Data | $25,417,000 | $32,654,000 | $33,687,000 | $26,081,000 |
| End Cash Position | $40,817,000 | $24,459,000 | $24,296,000 | $28,942,000 |
| Beginning Cash Position | $24,459,000 | $24,296,000 | $28,942,000 | $20,847,000 |
| Effect Of Exchange Rate Changes | $2,445,000 | $-2,721,000 | $470,000 | $-741,000 |
| Changes In Cash | $13,913,000 | $2,884,000 | $-5,116,000 | $8,836,000 |
| Net Issuance Payments Of Debt | $-74,587,000 | $-72,000,000 | $-88,000,000 | $362,019,000 |
| Net Long Term Debt Issuance | $-74,587,000 | $-72,000,000 | $-88,000,000 | $362,019,000 |
| Long Term Debt Payments | $-795,253,000 | $-823,000,000 | $-780,000,000 | $-897,981,000 |
| Long Term Debt Issuance | $720,666,000 | $751,000,000 | $692,000,000 | $1,260,000,000 |
| Net PPE Purchase And Sale | $-19,806,000 | $-13,084,000 | $-19,032,000 | $-21,785,000 |
| Purchase Of PPE | $-19,806,000 | $-13,084,000 | $-19,032,000 | $-21,785,000 |
| Change In Working Capital | $-11,453,000 | $-39,724,000 | $-39,579,000 | $-90,698,000 |
| Change In Other Working Capital | $-558,000 | $-193,000 | $-3,921,000 | $-2,242,000 |
| Change In Other Current Liabilities | $6,194,000 | $-4,248,000 | $-10,090,000 | $-256,000 |
| Change In Other Current Assets | $-13,159,000 | $-13,910,000 | $-21,845,000 | $-17,735,000 |
| Change In Payables And Accrued Expense | $5,164,000 | $11,879,000 | $29,274,000 | $13,302,000 |
| Change In Accrued Expense | $14,913,000 | $-2,834,000 | $14,425,000 | - |
| Change In Payable | $-9,749,000 | $14,713,000 | $14,849,000 | $13,302,000 |
| Change In Account Payable | $-9,749,000 | $14,713,000 | $14,849,000 | $13,302,000 |
| Change In Inventory | $-6,733,000 | $-31,633,000 | $14,071,000 | $-78,564,000 |
| Change In Receivables | $-2,361,000 | $-1,619,000 | $-47,068,000 | $-5,203,000 |
| Changes In Account Receivables | $-2,361,000 | $-1,619,000 | $-47,068,000 | $-5,203,000 |
| Other Non Cash Items | $28,597,000 | $-35,348,000 | $3,637,000 | $110,553,000 |
| Stock Based Compensation | $28,323,000 | $25,558,000 | $24,257,000 | $21,729,000 |
| Deferred Tax | $3,523,000 | $12,202,000 | $700,000 | $-6,042,000 |
| Deferred Income Tax | $3,523,000 | $12,202,000 | $700,000 | $-6,042,000 |
| Depreciation Amortization Depletion | $74,281,000 | $71,857,000 | $71,874,000 | $69,519,000 |
| Depreciation And Amortization | $74,281,000 | $71,857,000 | $71,874,000 | $69,519,000 |
| Amortization Cash Flow | $57,138,000 | $55,252,000 | $55,674,000 | $53,464,000 |
| Amortization Of Intangibles | $57,138,000 | $55,252,000 | $55,674,000 | $53,464,000 |
| Depreciation | $17,143,000 | $16,605,000 | $16,200,000 | $16,055,000 |
| Net Income From Continuing Operations | $47,055,000 | $132,423,000 | $64,459,000 | $-80,582,000 |
| Income Tax Paid Supplemental Data | - | $15,221,000 | $19,879,000 | $9,074,000 |
| Proceeds From Stock Option Exercised | - | $0 | $0 | $2,466,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-227,744,000 |
| Purchase Of Business | - | $0 | $0 | $-227,744,000 |
| Sale Of PPE | - | - | - | $0 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
| Asset Impairment Charge | - | - | - | - |
Fetched: 2026-07-14